Self-administered Berinert treats HAE at the first sign of an acute attack
Berinert is the only on-demand C1 esterase inhibitor (C1-INH) approved for treatment of acute abdominal,
facial, or laryngeal attacks of hereditary angioedema (HAE) in adults and pediatrics.
Berinert is approved for patient self-administration after proper training by a healthcare professional. The
safety and efficacy of Berinert for prophylactic therapy have not been established.
On-demand treatment helps patients take control of their HAE.
On-demand means treating with Berinert at the first sign of an HAE attack, which can occur suddenly,
frequently, and without warning. Patients might notice certain symptoms that signal the onset of an attack.
These warning signs can prompt early treatment—and early treatment can help reduce the time to relief.
Many patients develop symptoms that signal the onset of an acute HAE attack. Such symptoms as tingling, paresthesias, erythematous rash, fatigue, malaise, nausea, vomiting,
and abdominal pain have been described by patients with HAE. It is important to discuss these symptoms
with your patients so they can learn to recognize the early signs of an attack, and treat promptly.1
Berinert uses weight-based dosing of 20 IU/kg body weight, which ensures an optimized dose of C1-INH
during an attack.
In Clinical Trial
- Median time to onset of symptom relief is 48 minutes for abdominal or facial attack
- Median time to onset of symptom relief is 15 minutes for laryngeal attack
Make on-demand therapy your first-line therapy for HAE
All patients should have an on-demand treatment plan, even if they are on prophylactic therapy. Current
prophylactic therapies are not 100% effective and breakthrough attacks may occur. Even in cases where patients experience 2 to 4
attacks per month, patients may be able to better manage their HAE by treating each attack with Berinert at
the first sign.11
In fact, the World Allergy Organization (WAO) recommends that:11
- All attacks that result in debilitation or dysfunction and/or involve the face, the neck, or the abdomen
should be considered for on-demand treatment.
- Treatment of attacks affecting the upper airways is mandatory.
- Attacks should be treated as early as possible.
*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should
contact their physicians.
Learn about the mechanism of action and therapy features in the clinical overview of Berinert.